Creative Medical Technology Holdings is recruiting renowned stem cell clinical study experts to accelerate FDA approval

PHOENIX, June 22, 2021 / PRNewswire / – (OTC-CELZ) Creative Medical Technology Holdings today announced the appointment of Dr. Courtney Bartlett Head of clinical development of the therapeutic product pipeline of the company Dr. Bartlett has led clinical research in cell and gene therapy for more than a decade. She has co-investigated several widespread clinical stem cell studies conducted by public companies such as Capricor, TEVA, VeriCel, and Astellas. She has also published numerous articles, book chapters and poster presentations in the field of regenerative medicine.

“After working with the team on their StemSpine® program, I am very familiar with the excellent work done by Creative Medical Technology Holdings. This is one of the few companies that is developing both autologous and allogeneic cell treatments simultaneously, by a diverse group of indications for which there is no effective treatment, “said Dr. Bartlett. “It’s an exciting opportunity to work with such a dynamic and effective group of people on an advanced level.”

Creative Medical Technology Holdings has commercialized its autologous urology product Caverstem®, published clinical data on the treatment of low back pain with its patented StemSpine® approach, and has a diverse preclinical pipeline with ImmCelz®. One of Dr. Bartlett will be tasked with working with the FDA as the company works toward FDA approval for a new drug application to initiate clinical trials for the treatment of stroke.

“Dr. Bartlett has a unique blend of in-depth scientific knowledge, hands-on medical experience, and a brilliant data-driven mind. We are excited to have such a seasoned stem cell researcher join the company as we evolve.” of our robust portfolio, “said Timothy Warbington, President and CEO of the company.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial biotechnology company specializing in regenerative medicine / stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics, listed on the OTC under the ticker symbol CELZ. More information about the company can be found at

Forward-Looking Statements
OTC Markets has not reviewed this press release and assumes no responsibility for the adequacy or accuracy of this press release. This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical studies and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results could differ materially from those currently expected in such statements. See periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at

SOURCE Creative Medical Technology Holdings, Inc.

similar links